HAVCR2 and cancer: In addition, beyond PD-1/PD-L1 and CTLA-4-directed immunotherapies, T-cell immunoglobulin and mucin domain 3 (TIM-3), lymphocyte activation gene 3 (LAG-3), adoptive cell therapy (ACT), cytokine therapies, and cancer vaccines need to be investigated in combination with RT to enhance the immune response against TNBC tumors.